Principal Investigator

Anthony J
Jaslowski
Awardee Organization

St. Vincent Hospital
United States

Fiscal Year
2023
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Cancer Research of Wisconsin and Northern Michigan (CROWN) Consortium

The Cancer Research of Wisconsin and Northern Michigan (CROWN) Consortium is a collaboration between three of the largest cancer centers in Wisconsin: St. Vincent Hospital of the Hospital Sisters of the Third Order of St. Francis (St. Vincent Hospital through the Saint Vincent Hospital Cancer Centers (SVHCC)), Wheaton Franciscan Healthcare - Southeast Wisconsin, Inc., Columbia St. Mary’s, Inc., and Ministry Health Care, Inc. (Ascension Wisconsin (AW)), and Aspirus, Inc. (Aspirus). With SVHCC as the project/performance primary site, the three main institutions and their cooperating affiliates provide access to National Cancer Institute (NCI)-sponsored clinical trials to community members throughout Wisconsin and northern Michigan. The consortium covers an extensive catchment area that includes both rural and urban counties, as well as minority and underserved communities. The CROWN Consortium looks to broaden recruitment capabilities, regularly share best practices through established consortium committees, reach a more diversified patient portfolio, and implement cancer care delivery research (CCDR) at multiple affiliate locations. In addition, the consortium will actively participate and engage in NCORP Research Base trials beyond accrual by serving on committees, contributing to protocol development, and developing young investigators to be engaged with clinical research. The CROWN Consortium brings together an experienced research infrastructure with a multidisciplinary team of qualified investigators across many areas of clinical research including medical and radiation oncology, palliative care and pediatric oncology. The consortium provides a vast portfolio of cancer control, prevention, and care delivery, biospecimen, screening/post-treatment surveillance trials, as well as treatment and imaging clinical studies to the community setting. As a result, the CROWN Consortium will address gaps in clinical research in rural, urban, minority, and underserved populations. The CROWN Consortium will address this by the following specific aims: 1) Broaden CROWN Consortium participation in NCI-sponsored clinical trials by expanding recruitment, clinical capabilities, and sharing of resources; 2) Expand recruitment and retention of urban, rural, racial and ethnic minorities, and other underrepresented patient populations; 3) Execute highquality Cancer Care Delivery Research (CCDR) throughout the CROWN Consortium; and 4) Increase investigator engagement in NCORP initiatives by contributing to best practices and research findings. The CROWN Consortium represents a proven, high-performing addition to the NCORP network. The consortium will expand NCORP’s access to populations in Wisconsin and northern Michigan. The consortium will further NCORP Research Bases’ programs by providing a more representative population for studies, and by providing feedback on study design feasibility for community sites and for appropriateness for diverse participants. CROWN Consortium’s emphasis on understudied subgroups further underscores the value of CROWN Consortium to the NCORP network.

Publications

  • Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 10;39(23):2539-2551. Epub 2021 Jun 6. PMID: 34092112
  • Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Reply to T. Shimoi et al and Y. Shimanuki et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Nov 1;39(31):3522-3524. Epub 2021 Sep 23. PMID: 34554848
  • Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Jan 10;41(2):186-197. Epub 2022 Sep 27. PMID: 36166727
  • Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. 2024 Jan 18. Epub 2024 Jan 18. PMID: 38236702